article thumbnail

Arcturus Therapeutics Gets $1.3M

socalTECH

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech'

Arcturus 138
article thumbnail

Arcturus Therapeutics Gets $5M

socalTECH

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced.

Arcturus 153
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Arcturus Therapeutics Gets $220M More In Support For Vaccine Efforts

socalTECH

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.

Arcturus 113
article thumbnail

Sorrento Therapeutics Gets $2.3M

socalTECH

San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom.

Arcturus 100
article thumbnail

Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More

Xconomy

The money came from a wide range of backers, not just traditional biotech venture firms. billion, a figure compiled in the Venture Monitor Report. Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days.

Funding 52
article thumbnail

Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More

Xconomy

The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers.

Help 58